Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the cancer-treatment desk.
health
A BMJ clinical review describes how molecular classification, kidney-sparing treatment and immune-based combinations are shaping renal cell carcinoma care. It highlights improved outcomes in some settings alongside persistent resistance and a lack of validated biomarkers to guide treatment choice.
health
In a randomized phase 2 trial of 54 men with high-volume metastatic hormone-naive prostate cancer, talazoparib plus enzalutamide produced a high PSA response rate but no clear advantage over enzalutamide alone. Severe adverse events were more frequent with the combination, and two patients developed fatal acute myeloid leukaemia.